14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AXNX vs ABT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Abbott Laboratories (ABT) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas ABT carries 42.6/100 (HOLD) at $103.00 (17.4x Forward P/E, 15.7% operating margin).
Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. ABT 42.6/100 HOLD), ABT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (15.7% vs. N/A operating margin) and revenue trajectory (+14.5% vs. N/A YoY).
Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs ABT. Trailing 12-month operating profitability (AXNX N/A vs ABT 15.7%) and valuation multiples (AXNX N/M vs ABT 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ABT Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $179.9B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment41.5% of Rev ($20.0B)
90D Engineering Disclosures0 Published
Investor FAQ AXNX vs ABT Key Questions & Quantitative Answers
As of Nov 20, 2026, Abbott Laboratories (ABT) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas ABT carries 42.6/100 (HOLD) at $103.00 (17.4x Forward P/E, 15.7% operating margin). Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. ABT 42.6/100 HOLD), ABT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (15.7% vs. N/A operating margin) and revenue trajectory (+14.5% vs. N/A YoY). Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABT leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABT at +14.5% YoY revenue growth and -43.6% YoY earnings growth on $48.2B TTM revenue (57.2% gross margin, 15.7% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $48.2B for ABT. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 41.5% of Rev ($20.0B) (0 disclosures) for ABT.
ABT screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABT trades at 17.4x Forward P/E, 38.8x Trailing P/E, 1.50x PEG, and 4.3x EV/Revenue (23.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus ABT (9.1% ROE) capital efficiency.
In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ABT carries 112.5% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.04β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.